

**CLEARBRIDGE HEALTH LIMITED**  
(Incorporated in the Republic of Singapore)  
(Company Registration No. 201001436C)  
(the "**Company**")

---

**PROPOSED ACQUISITION OF SHARES IN PT INDO GENESIS MEDIKA**

- (1) **SUPPLEMENTAL DEED TO THE SALE AND PURCHASE AGREEMENT**
- (2) **REDEMPTION OF REDEEMABLE EXCHANGEABLE BOND**
- 

*Unless otherwise defined herein or the context otherwise requires, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Company's announcements dated 23 August 2018, 13 November 2018, 3 April 2019, 8 April 2019, 7 May 2019, 24 June 2019, 22 June 2020 and 30 September 2020 in relation to the Proposed Transactions ("**Announcements**").*

Further to the Announcements, the Board wishes to update shareholders of the Company that pursuant to:

- (i) the Letter Agreement to Third Tranche Payment Date, SAM has today paid to KPN the third tranche of the Consideration (being IDR2.0 billion (approximately S\$0.2 million<sup>1</sup>)); and
- (ii) the Letter Agreement to Redemption of Bond, KPN has today redeemed the REB and has paid to SAM the Redemption Amount (being IDR22.0 billion (approximately S\$2.0 million<sup>1</sup>) in cash) which was satisfied by (a) the payment in cash of IDR3.4 billion (approximately S\$0.3 million<sup>1</sup>), and (b) the novation of the Shareholders' Loan in aggregate principal amount of IDR18.6 billion (approximately S\$1.7 million<sup>1</sup>) based on the financial statements of the Target as at 31 July 2020 which had been extended by KPN to the Target, from KPN to SAM.

**BY ORDER OF THE BOARD**

Yee Pinh Jeremy  
Chief Executive Officer and Executive Director

6 October 2020

---

<sup>1</sup> All conversions of IDR to S\$ in this announcement are based on an exchange rate of S\$1:IDR 10,889 as at 5 October 2020 by the Monetary Authority of Singapore.

---

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*